Funding, M&A, exec moves and hiring — every signal, the moment it breaks.See plans →
Obsidian Therapeutics secures $350 million through a private placement. The funds will support its development of engineered tumor-infiltrating lymphocyte cell therapies.
RECENTLY ACQUIREDAug 03, 2026•5 days ago
Amount Raised
$350 Million
Round Type
Post-IPO Equity
CambridgeBiotechnologyHealth Care
Description
Obsidian Therapeutics, Inc. announced the completion of its private placement of $350 million. This funding will aid in the advancement of their innovative therapies. The transaction is part of their strategic partnership with Galera Therapeutics
Company Information
Company
Obsidian Therapeutics
Location
1030 Massachusetts Avenue, Suite 400
Cambridge, Massachusetts, United States
About
Obsidian Therapeutics, Inc. is a clinical biotechnology company pioneering engineered cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian’s proprietary cytoDRiVE® technology provides a way to precisely control the timing and level of protein function by using FDA approved small molecules. Obsidian is headquartered in Cambridge, Mass. The Company has collaborations with Bristol Myers Squibb and Vertex Pharmaceuticals. For more information, please visit www.obsidiantx.com and follow us on LinkedIn and Twitter.
Related People
Suggested for you
3 contacts
Verified contactsTodd H., Director Regulatory Affairs CMC hidden
Predictive Intelligence
Strategic
ML-powered predictions for Obsidian Therapeutics's next move
CambridgeBiotechnologyHealth Care